Return to content in this issue

 

Successful Desensitization to Daratumumab After a Severe Life-threatening Reaction in a Patient With Refractory Multiple Myeloma

Carrón-Herrero A1*, Solano-Solares E1*, Geraldine Rita C2, Rodríguez-Martín E2, Ruedas Á3, Barbolla I3, Berges-Gimeno MP1,4

1Allergology Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
2Immunology Department Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
3Internal Medicine Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
4Spanish Thematic Network and Co-operative Research Centres, ARADyAL, Spain
*Both authors contributed equally and should be considered first authors.

J Investig Allergol Clin Immunol 2021; Vol 31(6) : 511-513
doi: 10.18176/jiaci.0678

Key words: Daratumumab, Anaphylaxis, Desensitization, Multiple myeloma, Monoclonal antibody